China is the country with the highest number of diabetics worldwide, with around *** million people suffering from the disease. By the year 2050, it is predicted that China will have around *** million people with diabetes. Death from diabetes Diabetes is one of the leading causes of death worldwide, accounting for **** million deaths in 2021. Diabetes at least doubles one’s chance of dying prematurely, and many places in the world lack appropriate treatment options. The highest number of deaths from diabetes comes from the Western Pacific, where around *** million people died from the disease in 2024. Obesity One of the biggest risk factors for developing diabetes is being overweight or obese. Rates of obesity have increased in recent years in many countries around the world. In the United States, for example, it is estimated that around ** percent of the adult population was obese in 2023, compared to ** percent of the population in 2011.

In 2024, Pakistan had the highest prevalence of diabetes worldwide, with around ** percent of the population suffering from the disease. Diabetes mellitus, or simply, diabetes, refers to a group of metabolic disorders that cause high blood sugar levels. Diabetes can be prevented and treated though exercise, maintaining normal body weight, and healthy eating, but is usually managed with insulin injections. Costs As of 2024, there were almost *** million people worldwide who had diabetes. With such a huge number of people suffering from this disease, it is no surprise that spending on diabetes can be very high. It is estimated that the United States alone spent around ***** billion U.S. dollars on diabetes health expenditure in 2024. The countries with the highest spending per patient with diabetes include Switzerland, the United States, and Norway. Death Diabetes is among the leading ten causes of death worldwide, accounting for around **** million deaths in 2021. Complications resulting from diabetes include chronic kidney disease, stroke, and cardiovascular disease. The risk of early death is at least doubled among those with diabetes. The Western Pacific reports the highest number of deaths from diabetes, followed by North America and the Caribbean.

Diabetes prevalence is projected to increase across all world regions by 2050, with the Middle East and North Africa expected to face the highest rates at 21 percent. This alarming trend highlights the growing global health challenge posed by diabetes, which already affects hundreds of millions of people worldwide and strains healthcare systems. Global impact and economic burden The number of diabetics globally is set to rise from nearly 589 million in 2024 to around 853 million by 2050. This surge in cases is accompanied by a significant economic burden, with global expenditures for diabetes treatment expected to grow from about 1.02 trillion U.S. dollars in 2024 to approximately 1.04 trillion U.S. dollars by 2050. The United States alone is projected to spend around 404.5 billion U.S. dollars on diabetes-related healthcare in 2024, underscoring the massive financial implications of this chronic condition. Regional disparities and future outlook While the Middle East and North Africa region is projected to have the highest diabetes prevalence by 2050, other regions will also see substantial increases. Africa is expected to experience a 142 percent rise in diabetic cases from 2024 to 2050, despite having the lowest prevalence among world regions. China is anticipated to remain the country with the highest number of diabetics, reaching approximately 168 million cases by 2050. Notably, Pakistan is forecast to surpass the United States in terms of diabetic population by mid-century, reflecting shifting global health dynamics and the need for targeted interventions in developing nations.

The number of diabetics worldwide in 2024 was almost *** million. That number is expected to grow until at least the year 2050. The projected number of diabetics is expected to reach around *** million by that time. With an increased number of diabetics, the prevalence of diabetes is also projected to increase to around ** percent by 2050. Diabetes prevalence globally Diabetes is a chronic disease that affects the production and use of insulin in the body which affects blood glucose. Diabetes comes in two types, type 1 and type 2, which require different types of medical treatments. Globally, China, followed by India, has the largest number of diabetics as of 2024. Despite having the highest number of diabetics, China is not among the countries with the highest prevalence. Pakistan, followed by the Marshall Islands, had the highest prevalence of diabetics worldwide as of 2024. Diabetes pharmaceuticals Treatment for diabetes includes insulin, a hormone that regulates blood glucose, and pills to help regulate the effectiveness of insulin. Treatment depends on the type of diabetes. Danish drug manufacturer Novo Nordisk is one of the leading diabetes care companies in the world. In 2024, Novo Nordisk generated around *** billion kroner in revenue from its diabetes care segment.

The average for 2021 based on 27 countries was 6.24 percent. The highest value was in Spain: 10.3 percent and the lowest value was in Ireland: 3 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

By 2050, the Western Pacific region is forecast to have the highest number of diabetic people worldwide, with some 254 million people aged between 20 and 79 years. Diabetes in the future Between 2024 and 2050, the number of diabetics is set to increase in all regions worldwide. Diabetes rates are expected to increase the most in Africa, by roughly 142 percent. Throughout this period, Europe is projected to show the smallest increase, with about 10 percent. In 2050, the countries with the highest number of diabetics are expected to be China with some 168 million and India with about 157 million. At that time, about 43 million people are projected to have diabetes in the United States. Children with type 1 diabetes In 2024, the country with the highest estimated number of children and adolescents (between the ages of 0 and 19) with type 1 diabetes was India, which had some 301 thousand diabetic children and adolescents. The United States came second with around 197 thousand. Considering the U.S. population is significantly smaller than that of India, there is a higher percentage of children with type 1 diabetes in the United States.

Germany DE: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 6.900 % in 2021. This records an increase from the previous number of 5.300 % for 2011. Germany DE: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 6.100 % from Dec 2011 (Median) to 2021, with 2 observations. The data reached an all-time high of 6.900 % in 2021 and a record low of 5.300 % in 2011. Germany DE: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Germany – Table DE.World Bank.WDI: Social: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes. It is calculated by adjusting to a standard population age-structure.;International Diabetes Federation, Diabetes Atlas.;Weighted average;

Around ** percent of the global adult population suffered from diabetes in 2024 - by the year 2050 this number is expected to rise to ** percent. Diabetes, or diabetes mellitus, refers to a group of metabolic disorders that result in chronic high blood sugar levels. Diabetes can lead to serious health complications, such as cardiovascular disease, chronic kidney disease, and stroke, and is now among the top ten leading causes of death worldwide. Prevalence Diabetes is a global problem affecting many countries. China currently has the largest number of diabetics worldwide, with some *** million people suffering from the disease. However, the highest prevalence of diabetes is found in Pakistan, followed by the Marshall Islands and Kuwait. Rates of diabetes have increased in many countries in recent years, as have rates of obesity, one of the leading risk factors for the disease. Outlook It is predicted that diabetes will continue to be a problem in the future. Africa is expected to see a *** percent increase in the number of diabetics in the region from 2024 to 2050, while North America and the Caribbean are expected to see an increase of ** percent. In 2050, China is predicted to be the country with the highest number of diabetics worldwide, with the United States accounting for the fourth-highest number.

The average for 2021 based on 11 countries was 9.58 percent. The highest value was in Malaysia: 19 percent and the lowest value was in Vietnam: 6.1 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

In 2024, around 16 percent of adults between the ages of 20 and 79 had diabetes in Turkey. Other selected countries with a high prevalence of diabetes that year included Mexico, the United States, and Portugal. Diabetes is a metabolic disease that causes high blood sugar levels. Diabetes worldwide In 2024, an estimated 11 percent of the global adult population had diabetes. In concrete numbers, there were about 589 million diabetic adults (20-79 years) worldwide in 2024, and this total is predicted to grow to approximately 852.5 million by the year 2050. Spending per patient The country that spent the most on patients with diabetes in 2024 was Switzerland. At that time, providing for a diabetic patient in Switzerland cost an average of over 12 thousand U.S. dollars. The United States stood in second place, spending about 10,500 U.S. dollars per patient. In the same year, the ten countries by lowest average spending per person with diabetes were all African and Asian countries. Bangladesh had the lowest annual diabetes-related health expenditures per person, with just 74 U.S. dollars.

*(Age-standardised incidence rates per 100,000 individuals per year with 95% confidence intervals. † For cells labeled as NA, 95% CIs could not be estimated as there was only 1 data point).

Armenia AM: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 5.600 % in 2021. This records a decrease from the previous number of 8.500 % for 2011. Armenia AM: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 7.050 % from Dec 2011 (Median) to 2021, with 2 observations. The data reached an all-time high of 8.500 % in 2011 and a record low of 5.600 % in 2021. Armenia AM: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Armenia – Table AM.World Bank.WDI: Social: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes. It is calculated by adjusting to a standard population age-structure.;International Diabetes Federation, Diabetes Atlas.;Weighted average;

Chad TD: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 5.800 % in 2021. This records an increase from the previous number of 3.900 % for 2011. Chad TD: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 4.850 % from Dec 2011 (Median) to 2021, with 2 observations. The data reached an all-time high of 5.800 % in 2021 and a record low of 3.900 % in 2011. Chad TD: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Chad – Table TD.World Bank.WDI: Social: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes. It is calculated by adjusting to a standard population age-structure.;International Diabetes Federation, Diabetes Atlas.;Weighted average;

Aruba AW: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 4.300 % in 2021. This records a decrease from the previous number of 12.400 % for 2011. Aruba AW: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 12.100 % from Dec 2000 (Median) to 2021, with 3 observations. The data reached an all-time high of 12.400 % in 2011 and a record low of 4.300 % in 2021. Aruba AW: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Aruba – Table AW.World Bank.WDI: Social: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes. It is calculated by adjusting to a standard population age-structure.;International Diabetes Federation, Diabetes Atlas.;Weighted average;

ObjectiveDiabetes mellitus is an emerging epidemic in the Arab world. Although high diabetes prevalence is documented in Israeli Arabs, information from cohort studies is scant.MethodsThis is a population study, based on information derived between 2007–2011, from the electronic database of the largest health fund in Israel, among Arabs and Jews. Prevalence, 4-year-incidence and diabetes hazard ratios [HRs], adjusted for sex and the metabolic-syndrome [MetS]-components, were determined in 3 age groups (

Belarus BY: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 5.600 % in 2021. This records a decrease from the previous number of 8.000 % for 2011. Belarus BY: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 6.800 % from Dec 2011 (Median) to 2021, with 2 observations. The data reached an all-time high of 8.000 % in 2011 and a record low of 5.600 % in 2021. Belarus BY: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Belarus – Table BY.World Bank.WDI: Social: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes. It is calculated by adjusting to a standard population age-structure.;International Diabetes Federation, Diabetes Atlas.;Weighted average;

Diabetes Diet Market Outlook

The global diabetes diet market size was valued at approximately USD 8.5 billion in 2023, projected to grow at a robust CAGR of 5.9% reaching around USD 14.9 billion by 2032. This growth trajectory is primarily fueled by the increasing prevalence of diabetes worldwide, which is urging a shift towards specialized dietary plans to manage the condition effectively. The burgeoning awareness regarding the benefits of a diabetes-specific diet, combined with an increase in health-consciousness among consumers, is driving significant demand in this market. Furthermore, the technological advancements in food processing and the introduction of innovative diabetes-friendly products are anticipated to bolster market expansion over the coming years.

The surge in diabetic populations globally is a major growth factor for the diabetes diet market. In many parts of the world, lifestyle changes and dietary shifts have led to a sharp rise in diabetes cases, particularly Type 2 diabetes. With urbanization, sedentary lifestyles, and the prevalence of unhealthy eating habits contributing to this rise, the need for dietary interventions has become more pronounced. Diabetes-specific diets play a crucial role in managing blood glucose levels, which in turn reduces the risk of complications associated with the disease. As healthcare professionals increasingly recommend tailored diet plans as part of diabetes management, the demand for specialized products continues to rise, fostering market growth.

The growing geriatric population also contributes significantly to the diabetes diet market’s expansion. Older individuals are more susceptible to Type 2 diabetes due to various factors, including reduced physical activity and metabolic changes. This demographic shift is leading to an increased market for diabetes-friendly dietary solutions tailored to meet the nutritional needs of older adults. Moreover, as life expectancy increases, the need for long-term diabetes management solutions, including appropriate diets, becomes more critical, further propelling market demand. The development of age-specific dietary products that cater to the geriatric population's unique requirements is becoming a focal point for manufacturers, thus driving innovation in the market.

Technological advancements and product innovation are also key drivers of market growth. The introduction of low-calorie sweeteners, meal replacements, and low-carbohydrate foods offers diabetic consumers a wider variety of choices that cater to their nutritional needs and preferences. These innovations are driven by a surge in research and development efforts aimed at enhancing the nutritional content and taste of diabetes-friendly products. Additionally, the growing trend of personalized nutrition, which involves tailoring diet plans based on individual health conditions, is encouraging manufacturers to invest in novel food solutions. This trend is expected to continue fueling the diabetes diet market as consumers seek products that align with their health goals and dietary restrictions.

The regional outlook for the diabetes diet market is promising, with North America leading due to its high diabetes prevalence and well-established healthcare infrastructure. In Europe, the market is driven by increasing health-consciousness and governmental initiatives promoting healthy lifestyles. The Asia Pacific region, exhibiting the highest growth rate, is fueled by rising diabetes incidences and growing awareness about diabetes management. Latin America and the Middle East & Africa are also witnessing market expansion due to improved healthcare access and increasing diabetes awareness campaigns. Each region's unique demographic and economic factors are shaping the growth trajectory of the diabetes diet market and creating opportunities for tailored market strategies.

Product Type Analysis

The diabetes diet market, segmented by product type, encompasses meal replacements, low-calorie sweeteners, low-carbohydrate foods, and other tailored food products. Meal replacements are gaining traction as they offer convenient solutions for individuals managing their diabetes. These products are designed to provide balanced nutrition while controlling carbohydrate intake, making them attractive to busy consumers. The market for meal replacements is being driven by the demand for easy-to-prepare options that do not compromise on nutritional value. Manufacturers are increasingly focusing on enhancing the taste and texture of these products to appeal to a wider audience, further driving their popularity.

Low-calorie

Diabetes continues to be a significant global health concern, with the Western Pacific region reporting the highest number of diabetes-related deaths in 2024, with around 1.2 million. This stark figure underscores the urgent need for improved diabetes prevention and management strategies worldwide. North America and the Caribbean followed with an estimated 526,000 deaths, while Africa is had the lowest number at 216,000. Regional disparities and global impact The prevalence of diabetes varies significantly across regions, reflecting differences in healthcare systems, lifestyle factors, and genetic predispositions. In the United States, the death rate from diabetes mellitus was 22.4 per 100,000 people in 2023, with 8.4 percent of the adult population living with the condition. Canada has seen a slight decrease in its diabetes-related death rate, falling from 21.8 per 100,000 in 2000 to 18.1 per 100,000 in 2023. These figures highlight the ongoing challenges in managing diabetes, even in countries with advanced healthcare systems. European landscape and global context Within Europe, Germany reported the highest number of diabetes-related deaths in 2024, with nearly 63,000 fatalities among adults aged 20 to 79 years. Italy followed closely with around 62,400 deaths. However, Czechia reported the highest mortality rates in Europe as of 2022, with 43.4 diabetes deaths per 100,000 population overall. On a global scale, diabetes remains a major health concern, with 19 percent of adults worldwide identifying it as one of the biggest health problems in their country.

Diabetes Treatment Market Outlook

According to our latest research, the global Diabetes Treatment Market size reached USD 82.6 billion in 2024, driven by rising diabetes prevalence and ongoing innovation in therapeutic approaches. The market is expected to expand at a CAGR of 6.5% from 2025 to 2033, projecting a value of approximately USD 145.2 billion by 2033. This robust growth trajectory is primarily attributed to escalating patient populations, advancements in drug delivery mechanisms, and increased awareness around diabetes management.

One of the most significant growth factors for the diabetes treatment market is the global surge in diabetes incidence, particularly Type 2 diabetes. Sedentary lifestyles, unhealthy dietary patterns, and rising obesity rates are fueling the expansion of the diabetic population, especially in emerging economies. The World Health Organization estimates that over 537 million adults were living with diabetes in 2024, a number expected to rise sharply in the coming years. This expanding patient base is generating heightened demand for both insulin and non-insulin therapies, as well as for innovative monitoring and delivery solutions. Pharmaceutical companies are responding by accelerating research and development efforts, resulting in a robust pipeline of new products and combination therapies that address the evolving needs of diabetic patients.

Technological advancements are another powerful driver in the diabetes treatment market. The introduction of next-generation insulin analogs, continuous glucose monitoring (CGM) systems, and smart insulin pens has revolutionized diabetes care, offering patients improved glycemic control and enhanced quality of life. The integration of digital health tools and telemedicine platforms is further transforming disease management, enabling real-time monitoring, personalized treatment adjustments, and improved patient engagement. These innovations are not only improving clinical outcomes but also reducing the burden on healthcare systems by minimizing complications and hospitalizations. As a result, the adoption of advanced diabetes management solutions is accelerating across both developed and developing regions.

Government initiatives and supportive reimbursement policies are also playing a pivotal role in market growth. Many countries are prioritizing diabetes care within their public health agendas, allocating substantial resources for early diagnosis, patient education, and subsidized access to essential medications. Strategic collaborations between public and private stakeholders are fostering the development and distribution of affordable treatment options, particularly in low- and middle-income countries. Additionally, the increasing availability of generic drugs and biosimilars is enhancing market accessibility, further driving the adoption of diabetes therapies worldwide. These collective efforts are expected to sustain the momentum of the diabetes treatment market over the forecast period.

From a regional standpoint, North America continues to dominate the diabetes treatment market, accounting for the largest revenue share in 2024. This leadership is underpinned by a high prevalence of diabetes, robust healthcare infrastructure, and early adoption of advanced therapeutic modalities. Europe follows closely, supported by comprehensive reimbursement frameworks and a strong focus on research and innovation. However, the Asia Pacific region is emerging as the fastest-growing market, propelled by rising disease incidence, expanding healthcare access, and increasing investments by global pharmaceutical companies. The Middle East & Africa and Latin America are also witnessing steady growth, driven by improved awareness and government-led initiatives to combat diabetes.

Product Type Analysis

The Product Type segment of the diabetes treatment market encompasses insulin, oral antidiabetic drugs, non-insulin injectable drugs, and other therapies. Insulin

AimTo report the point prevalence, deaths and disability-adjusted-life-years (DALYs) due to type 2 diabetes and its attributable risk factors in 204 countries and territories during the period 1990-2019.MethodsWe used the data of the Global Burden of Disease (GBD) Study 2019 to report number and age-standardised rates per 100 000 population of type 2 diabetes. Estimates were reported with 95% uncertainty intervals (UIs).ResultsIn 2019, the global age-standardised point prevalence and death rates for type 2 diabetes were 5282.9 and 18.5 per 100 000, an increase of 49% and 10.8%, respectively, since 1990. Moreover, the global age-standardised DALY rate in 2019 was 801.5 per 100 000, an increase of 27.6% since 1990. In 2019, the global point prevalence of type 2 diabetes was slightly higher in males and increased with age up to the 75-79 age group, decreasing across the remaining age groups. American Samoa [19876.8] had the highest age-standardised point prevalence rates of type 2 diabetes in 2019. Generally, the burden of type 2 diabetes decreased with increasing SDI (Socio-demographic Index). Globally, high body mass index [51.9%], ambient particulate matter pollution [13.6%] and smoking [9.9%] had the three highest proportions of attributable DALYs.ConclusionLow and middle-income countries have the highest burden and greater investment in type 2 diabetes prevention is needed. In addition, accurate data on type 2 diabetes needs to be collected by the health systems of all countries to allow better monitoring and evaluation of population-level interventions.